182 related articles for article (PubMed ID: 1350457)
21. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse.
Roux-Dosseto M; Romain S; Dussault N; Desideri C; Piana L; Bonnier P; Tubiana N; Martin PM
Eur J Cancer; 1992; 28A(10):1600-4. PubMed ID: 1356387
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
Meyers SL; O'Brien MT; Smith T; Dudley JP
Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
[TBL] [Abstract][Full Text] [Related]
23. int-2 oncogene amplification and prognosis in node-negative breast carcinoma.
Fioravanti L; Cappelletti V; Coradini D; Miodini P; Borsani G; Daidone MG; Di Fronzo G
Int J Cancer; 1997 Dec; 74(6):620-4. PubMed ID: 9421359
[TBL] [Abstract][Full Text] [Related]
24. Steroid hormone receptor immunohistochemistry and amplification of c-myc protooncogene. Relationship to disease-free survival in breast cancer.
Pertschuk LP; Feldman JG; Kim DS; Nayeri K; Eisenberg KB; Carter AC; Thelmo WT; Rhong ZT; Benn P; Grossman A
Cancer; 1993 Jan; 71(1):162-71. PubMed ID: 8416713
[TBL] [Abstract][Full Text] [Related]
25. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.
Hui R; Campbell DH; Lee CS; McCaul K; Horsfall DJ; Musgrove EA; Daly RJ; Seshadri R; Sutherland RL
Oncogene; 1997 Sep; 15(13):1617-23. PubMed ID: 9380415
[TBL] [Abstract][Full Text] [Related]
26. Oncogene amplifications in early-stage human prostate carcinomas.
Latil A; Baron JC; Cussenot O; Fournier G; Boccon-Gibod L; Le Duc A; Lidereau R
Int J Cancer; 1994 Dec; 59(5):637-8. PubMed ID: 7960236
[TBL] [Abstract][Full Text] [Related]
27. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Rydén S; Sigurdsson H
Cancer Lett; 1994 Jun; 81(2):137-44. PubMed ID: 7912163
[TBL] [Abstract][Full Text] [Related]
28. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
[TBL] [Abstract][Full Text] [Related]
29. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
30. HER-2/neu oncogene: what does amplification mean?
Pavy JJ; Descotes F; Adessi GL
Br J Cancer; 1993 Jul; 68(1):214-5. PubMed ID: 8100444
[No Abstract] [Full Text] [Related]
31. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
32. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
33. Assessing sequential oncogene amplification in human breast cancer.
Janocko LE; Lucke JF; Groft DW; Brown KA; Smith CA; Pollice AA; Singh SG; Yakulis R; Hartsock RJ; Shackney SE
Cytometry; 1995 Sep; 21(1):18-22. PubMed ID: 8529465
[TBL] [Abstract][Full Text] [Related]
34. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
35. DNA amplification of HER-2/neu and INT-2 oncogenes in epithelial ovarian cancer.
Medl M; Sevelda P; Czerwenka K; Dobianer K; Hanak H; Hruza C; Klein M; Leodolter S; Müllauer-Ertl S; Rosen A
Gynecol Oncol; 1995 Dec; 59(3):321-6. PubMed ID: 8522248
[TBL] [Abstract][Full Text] [Related]
36. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
37. Protooncogene amplification and tumor ploidy in human ovarian neoplasms.
Sasano H; Garrett CT; Wilkinson DS; Silverberg S; Comerford J; Hyde J
Hum Pathol; 1990 Apr; 21(4):382-91. PubMed ID: 1969381
[TBL] [Abstract][Full Text] [Related]
38. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
39. BCL-1 participates in the 11q13 amplification found in breast cancer.
Theillet C; Adnane J; Szepetowski P; Simon MP; Jeanteur P; Birnbaum D; Gaudray P
Oncogene; 1990 Jan; 5(1):147-9. PubMed ID: 2181375
[TBL] [Abstract][Full Text] [Related]
40. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
